Company Profile
Akebia Therapeutics
Company Overview
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts and a Global leader in hypoxia inducible factor (HIF) Biology, focused on delivering innovative therapies to patients with kidney disease and pursuing advances across multiple disease states through HIF biology.
Akebia's lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia's global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia secondary to chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing. For more information, please visit our website at www.akebia.com.
Company History
We were founded in 2007 to discover and develop novel therapeutic solutions leveraging hypoxia inducible factor—or HIF—biology, a primary regulator involved in multiple major biological pathways.